文献速递瓣膜外科

经心尖经导管二尖瓣植入术中基于系绳装置的二次重新张紧

Secondary retensioning of a tether-based device for transapical transcatheter mitral valve implantation.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

这项多中心研究纳入2017至2021年18例接受二次系绳重新张紧的患者,其中11例有完整数据。结果显示无急性并发症及死亡,出院时91%患者二尖瓣周漏完全消除,30天器械成功率达82%。作者认为该操作在多数患者中技术可行、安全且急性期有效。

要点

  • 经心尖二尖瓣植入术后因假体移位导致明显瓣周漏时,可尝试通过重新张紧系绳复位瓣膜支架。
  • 本组11例可分析患者中,出院时91%(N=10)瓣周漏完全消除,仅1例残留中度瓣周漏。
  • 30天器械成功率82%(N=9),无30天死亡,2例因持续或复发性瓣周漏需行开放二尖瓣置换。

核心结论

  • 该多中心研究显示,在多数患者中重新张紧系绳操作技术可行、围术期安全且急性期有效。
  • 作者认为,经心尖经导管二尖瓣植入术中系绳可重新张紧的特性可能为外科高危人群提供额外的管理优势。

研究设计与样本

  • 多中心研究,2017至2021年共识别18例接受二次系绳重新张紧的患者,其中11例有基线、手术及随访数据并纳入分析。
  • 数据分析依据二尖瓣研究联盟(Mitral Valve Research Consortium)定义进行,连续变量以中位数及四分位距表示。

主要发现

  • 全部患者年龄75岁(73.5,85.0),男性64%(N=7),EuroSCORE II 6.2%(5.8,11.6)。
  • 所有患者术后均存在瓣周漏,其中63.6%(N=7)为瓣周漏≥3+,54%(N=6)有溶血征象,91%(N=10)纽约心脏协会(NYHA)心功能≥III级。
  • 操作结果无急性并发症、无死亡;出院时91%(N=10)患者瓣周漏完全消除,1例残留中度瓣周漏。
  • 30天时二尖瓣研究联盟器械成功率为82%(N=9);2例因持续和复发性瓣周漏需行开放二尖瓣置换。
  • 在重新张紧操作成功的患者中,89%(N=8)NYHA心功能为I/II级;无30天死亡。

临床怎么用

  • 作者认为,经心尖经导管二尖瓣植入术中系绳可重新张紧的特性可能为外科高危人群提供额外的管理优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Relevant paravalvular leakage (PVL) due to prosthesis dislodgement is a rare but potentially severe complication after transcatheter mitral valve implantation (TMVI). Due to the epicardial anchoring mechanism of the Tendyne® TMVI system, repositioning of the valve stent may be possible by retensioning of the tether. This multicentre study aimed to investigate the procedural and short-term safety as well as efficacy of retensioning manoeuvres. METHODS: From 2017 to 2021, N = 18 patients who underwent secondary tether retensioning were identified. Baseline, procedural and follow-up data were available from N = 11 patients and analysed according to the Mitral Valve Research Consortium definitions. Continuous variables are shown as median with interquartile range. RESULTS: All patients [age 75 years (73.5, 85.0), 64% male (N = 7), EuroSCORE II 6.2% (5.8, 11.6)] presented with post-procedural PVL [63.6% (N = 7) with PVL ≥3+]. Of these, 54% (N = 6) showed signs of haemolysis. The majority were severely symptomatic [New York Heart Association ≥III (91%, N = 10)]. Procedural outcomes revealed no acute complications and no mortality. At discharge, PVL was completely eliminated in 91% (N = 10) of patients with 1 case of remaining moderate PVL. At 30 days, Mitral Valve Research Consortium device success was achieved in 82% (N = 9) of patients. Two patients required open surgical mitral valve replacement due to persistent and recurrent PVL. In 89% (N = 8) of patients with successful retensioning procedure, New York Heart Association class was I/II. There was no 30-day mortality. CONCLUSIONS: This multicentre study demonstrates technical feasibility, procedural safety and acute efficacy of retensioning procedures in the majority of patients. The potential to retension the tether in transapical TMVI may provide additional management advantages in populations at high surgical risk.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Beyer M, Muller D, De Marco F, et al. Secondary retensioning of a tether-based device for transapical transcatheter mitral valve implantation. Eur J Cardiothorac Surg. 2024. PMID: 38152923. doi:10.1093/ejcts/ezad430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。